Status of tumor markers in epithelial ovarian cancer has there been any progress? A review

被引:45
作者
Husseinzadeh, Nader [1 ]
机构
[1] Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Cincinnati, OH 45267 USA
关键词
Epithelial ovarian cancer; Screening ovarian tumor markers; C-REACTIVE PROTEIN; ENDOTHELIAL GROWTH-FACTOR; SERUM CA-125 LEVELS; EARLY-STAGE; PROTEOMIC PATTERNS; PROGNOSTIC-FACTOR; BIOMARKERS; EXPRESSION; MULTIPLE; IDENTIFICATION;
D O I
10.1016/j.ygyno.2010.09.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The aim is to present an overview of tumor markers other than CA-125 that have been proposed for use in the diagnosis of epithelial ovarian cancer and explore molecular studies which have been used to identify genomic and proteomic changes associated with this malignancy for possible future development of more sensitive tumor markers. Methods. A Medline search was conducted to review published articles from American and European studies from 1990 to 2010, related to tumor markers for ovarian cancer. Different methods such as genomic, proteomic and transcriptional profiling were used to identify new tumor markers for clinical use. Results. A few of the newer tumor markers alone have demonstrated equal or slightly higher sensitivity to CA-125. Improved sensitivity and specificity have been reported using these new markers combined with CA-125. Conclusion. Addition of new tumor markers as a compliment to CA-125 were associated with higher sensitivity and detection rates than either marker alone. However, the low prevalence of ovarian cancer necessitates a higher level of sensitivity and specificity that has still not been achieved if these biomarkers are used for diagnosis and monitoring the disease progress as a result of low positive predictive value. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:152 / 157
页数:6
相关论文
共 64 条
  • [1] Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis
    Andersen, John D.
    Boylan, Kristin L. M.
    Xue, Feifei S.
    Anderson, Lorraine B.
    Witthuhn, Bruce A.
    Markowski, Todd W.
    Higgins, LeeAnn
    Skubitz, Amy P. N.
    [J]. ELECTROPHORESIS, 2010, 31 (04) : 599 - 610
  • [2] Combining a symptoms index with CA 125 to improve detection of ovarian cancer
    Andersen, M. Robyn
    Goff, Barbara A.
    Lowe, Kimberly A.
    Scholler, Nathalie
    Bergan, Lindsay
    Dresher, Charles W.
    Paley, Pamela
    Urban, Nicole
    [J]. CANCER, 2008, 113 (03) : 484 - 489
  • [3] Use of a symptom index, CA125 and HE4 to predict ovarian cancer
    Goff, B.
    Andersen, M.
    Lowe, K.
    Scholler, N.
    Bergan, L.
    Drescher, C.
    Paley, P.
    Urban, N.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S103 - S103
  • [4] Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study
    Anderson, Garnet L.
    McIntosh, Martin
    Wu, Lieling
    Barnett, Matt
    Goodman, Gary
    Thorpe, Jason D.
    Bergan, Lindsay
    Thornquist, Mark D.
    Scholler, Nathalie
    Kim, Nam
    O'Briant, Kathy
    Drescher, Charles
    Urban, Nicole
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (01): : 26 - 38
  • [5] [Anonymous], SEER SURVIVAL MONOGR
  • [6] Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment
    Badgwell, Donna
    Lu, Zhen
    Cole, Laurence
    Fritsche, Herbert
    Atkinson, Edward N.
    Somers, Elizabeth
    Allard, Jeffrey
    Moore, Richard G.
    Lu, Karen H.
    Bast, Robert C., Jr.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 106 (03) : 490 - 497
  • [7] New tumor markers: CA125 and beyond
    Bast, RC
    Badgwell, D
    Lu, Z
    Marquez, R
    Rosen, D
    Liu, J
    Baggerly, KA
    Atkinson, EN
    Skates, S
    Lokshin, A
    Menon, U
    Jacobs, I
    Lu, K
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 : 274 - 281
  • [8] Bast RJ., 2003, J Clin Oncol, V21, p200s
  • [9] Bast Robert C Jr, 2002, Cancer Treat Res, V107, P61
  • [10] Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer
    Brakora, KA
    Lee, H
    Yusuf, R
    Sullivan, L
    Harris, A
    Colella, T
    Seiden, MV
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 361 - 365